Leishen Energy Holding Co., Ltd. engages in the provision of clean-energy equipment and integrated solutions to the oil and gas industry. It operates through the following business segments; Clean-Energy Equipment; Oil and Gas Engineering Technical Services; New Energy Production and Operation; Digitalization and Integration Equipment; The Clean-Energy Equipment segment supplies wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment and polymer flexible composite pipes. The Oil and Gas Engineering Technical Services segment provides customers with a products and technical solutions for oil and gas production. The New Energy Production and Operation segment focuses on the production, storage and transportation of natural gas, traditional fuels, development of distributed energy, and the planning and operation of new energy and new energy industries. The Digitalization and Integration Equipment segment designed to provide informatization solutions for industrial intelligence, mobility, industrial interconnection and big data trends. The company was founded by Hongqi Li in 2007 and is headquartered in Beijing, China.
相关临床试验
14
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1895
进行中（未招募）
1
7.1%
已完成
10
71.4%
尚未招募
2
14.3%
招募中
1
7.1%
暂无批准数据
- A new study published in BMJ Medicine found that only 45% of Medicare beneficiaries who received FDA accelerated approval cancer drugs were treated with medications that ultimately improved survival. - Between 2012 and 2020, 178,000 Medicare beneficiaries accessed early cancer treatments through the accelerated pathway, generating 76,000 additional life-years at an average cost of $263,000 per year. - Medicare spent over $20 billion more on accelerated approval drugs compared to alternative treatments, with costs ranging from $26,000 per life-year for melanoma drugs to $4.5 million for some breast cancer treatments. - Just three drugs for melanoma and lung cancer accounted for over two-thirds of all survival benefits, highlighting the concentrated nature of therapeutic gains from the program.
- Medicare's first round of drug price negotiations achieved reductions ranging from 8% to 42% across ten medications, with sitagliptin showing the most significant price decrease. - Despite negotiated reductions, nine out of ten drugs remain more expensive in the U.S. compared to six other high-income countries, with only insulin aspart reaching international price levels. - Analysis reveals strategic pricing patterns, with biologics like etanercept, ibrutinib, and ustekinumab seeing 33-40% reductions, while negotiations appeared to align drug prices with therapeutic value.
